Fan, Bin
Mellinghoff, Ingo K.
Wen, Patrick Y.
Lowery, Maeve A.
Goyal, Lipika
Tap, William D.
Pandya, Shuchi S.
Manyak, Erika
Jiang, Liewen
Liu, Guowen
Nimkar, Tara
Gliser, Camelia
Prahl Judge, Molly
Agresta, Sam
Yang, Hua
Dai, David
Funding for this research was provided by:
Agios Pharmaceuticals, Inc. (Not applicable)
Article History
Received: 13 February 2019
Accepted: 28 March 2019
First Online: 26 April 2019
Compliance with ethical standards
:
: B. Fan, S.S. Pandya, E. Manyak, L. Jiang, G. Liu, T. Nimkar, C. Gliser, M. Prahl Judge, and H. Yang are employees and stockholders of Agios. S. Agresta and D. Dai were employees and stockholders of Agios at the time of the study. E. Manyak was an employee of Agios at the time of the study and current stockholder of Agios. I.K. Mellinghoff has received research funding from General Electric, Amgen, and Lilly; has advisory roles with Agios, Puma Biotechnology, and Debiopharm Group; and has received an honorarium from Roche for a presentation. P.Y. Wen has participated in advisory boards for Abbvie, Agios, AstraZeneca, Blue Earth Diagnostics, Eli Lilly, Genentech/Roche, Immunomic Therapeutics, Kadmon, Kiyatec, Puma, Vascular Biogenics, Taiho, Deciphera, and VBI Vaccines; has acted as speaker for Merck and Prime Oncology; has received research support from Agios, AstraZeneca, Beigene, Eli Lily, Genentech/Roche, Karyopharm, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Sanofi-Aventis, and VBI Vaccines. M.A. Lowery is a consultant and advisory board member for Agios and an advisory board member for Celgene, EMD Serono, and Roche. L. Goyal is an advisory board member for Pieris Pharmaceuticals and Debiopharm. W.D. Tap has received clinical trial funding from Agios during the conduct of the study; personal fees from Eli Lilly, EMD Serono, Novartis, Eisai, Janssen, Immune Design, Adaptimmune, Daiichi Sankyo, Blueprint, Loxo, GlaxoSmithKline, Agios, and Plexxikon; holds a patent for Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI; a patent for Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy - 62/671,625 pending to MSKCC/SKI; is a scientific advisory board member and stock owner for Certis Oncology Solutions and Atropos Therapeutics.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.